Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.71 |
| ▸ | CDK4 | P11802 | 5/20 | 0.67 |
| ▸ | CCND1 | P24385 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19789867 | 1.00 | SIRT1 (0.71) | SIRT1CDK4CCND1NPC1RAB9A | |
| SCHEMBL761706 | 0.79 | MEN1 (0.75) | SIRT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17037428 | 0.78 | MEN1 (0.70) | SIRT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5459439 | 0.77 | SIRT1 (0.61) | SIRT1CDK4CCND1NPC1RAB9A | |
| SCHEMBL5459435 | 0.77 | SIRT1 (0.61) | SIRT1CDK4CCND1NPC1RAB9A | |
| SCHEMBL12894877 | 0.77 | GOT1 (0.67) | CDK4CCND1NPC1RAB9AMEN1 | |
| SCHEMBL18595162 | 0.75 | MEN1 (0.76) | SIRT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6365945 | 0.74 | MEN1 (0.65) | SIRT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4331421 | 0.74 | MEN1 (1.00) | SIRT1CDK4CCND1NPC1RAB9A | |
| SCHEMBL7677879 | 0.74 | MEN1 (0.67) | SIRT1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2393787-B1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2016-06-02 | — | — | US | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010091384-A2 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | SIRT1 2147/4885CDK4 1363/4885CCND1 3379/4885 |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | SIRT1 2147/4885CDK4 1363/4885CCND1 3379/4885 |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | CDH1, DSC1, EPCAM | SIRT1 1844/4885CDK4 1426/4885CCND1 1417/4885 |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | CDH1, GPR119, FABP4 | SIRT1 915/4885CDK4 2775/4885CCND1 3790/4885 |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | CDH1, ICAM1, S100A11 | SIRT1 2147/4885CDK4 1363/4885CCND1 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.